Biomerica (BMRA) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomerica (BMRA) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 34.4% versus a loss of 85.1%. Anbio Biotechnology is the larger company by market cap ($202.8 million vs $8.7 million), about 23.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | NNNN |
|---|---|---|
| Share price | $1.89 | $4.62 |
| Market cap | $8.69M | $202.78M |
| 1-day change | -0.53% | -5.71% |
| YTD return | -25.00% | -84.64% |
| 1-year return | -34.38% | -85.09% |
| 5-year return | -95.74% | — |
| P/E ratio (TTM) | — | 30.80 |
| Forward P/E | 4.85 | — |
| EPS (TTM) | $-1.30 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $44.73 |
| 52-week low | $1.45 | $4.55 |
| Distance from 52-week high | -41.12% | -89.67% |
| Average volume | 70.88K | 146.84K |
| Shares outstanding | 4.60M | 43.89M |
| Employees | 50 | 27 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology is about 23.3 times larger than Biomerica by market value ($202.78M vs $8.69M).
- BMRA has outperformed NNNN by 50.7 percentage points over the past year.
- The two companies sit in different sectors: Biomerica in Healthcare and Anbio Biotechnology in Health Care.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Healthcare · Medical Devices · 50 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
BMRA vs NNNN FAQ
Which is bigger, Biomerica or Anbio Biotechnology?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $202.78M compared with $8.69M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or NNNN?
BMRA returned -34.38% over the past 12 months, compared with -85.09% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and Anbio Biotechnology in the same industry?
No. Biomerica is in the Healthcare sector, while Anbio Biotechnology is in Health Care.